Myriad Genetics Inc. reports developments in molecular diagnostic testing and precision medicine, with recurring updates on tests that assess disease risk, disease progression, and treatment selection across medical specialties. Company news commonly covers the Cancer Care Continuum, Prenatal Health, and Mental Health businesses, including test volume trends, average revenue per test, earnings results, and financial guidance.
Updates also address Myriad's oncology diagnostics and research programs, including MyChoice CDx, Precise MRD, Prolaris, hereditary cancer testing, GeneSight, and prenatal testing products. News themes include companion diagnostic approvals, clinical data presentations, commercial launches, collaborations, and investor healthcare conference participation.
Myriad Genetics (MYGN) released new MONSTAR-SCREEN-3 study data on post-surgical residual cancer detection in resectable colorectal and pancreatic cancers. The ongoing study evaluates Precise MRD, a whole-genome sequencing-based test for molecular residual disease, or cancer traces remaining after treatment.
In colorectal cancer, circulating tumor DNA detected one month after surgery was associated with disease progression. Detection preceded all observed clinical recurrences by a median four months; more than half of post-surgical positive patients were detected below 100 parts per million. Initial pancreatic cancer findings showed significantly worse recurrence-free survival in patients with detectable residual disease one month after surgery than in those without it. Myriad said the results support the test's potential for earlier risk assessment.
Myriad Genetics (NASDAQ: MYGN) signed a definitive agreement to sell its Prenatal Health testing business to Labcorp for $210 million in cash. The purchase price also includes the business’s inventory value at closing. The sale covers the Prequel, Foresight, SneakPeek and FirstGene tests and is expected to close by early 2027, subject to regulatory clearance and customary closing conditions.
Myriad expects the transaction to improve its revenue growth and profitability and strengthen its balance sheet to support investment in cancer care priorities. The prenatal portfolio served over 600,000 patients over the last twelve months. Labcorp (NYSE: LH) expects approximately $160 million in revenue in year one, slight accretion to adjusted earnings in year one, and average diagnostics segment margins by the end of year two, once fully integrated.
Myriad Genetics (NASDAQ: MYGN) will release its third quarter 2026 financial results after market close on November 4, 2026. Management will host an earnings conference call at 4:30 pm ET that day to provide a financial overview and business update. A live webcast and subsequent replay will be available on the company’s Investor Relations website.
Myriad Genetics (MYGN) and SOPHiA GENETICS (SOPH) announced a collaboration to advance prostate cancer genomic instability score technology with AstraZeneca. Myriad’s PrGIS is a biomarker signature designed to assess chromosome instability associated with homologous recombination deficiency, an impaired DNA repair process. The collaboration aims to advance PrGIS in clinical trials and develop potential companion diagnostics, tests used to guide treatment selection.
Myriad’s MyChoice CDx, currently a companion diagnostic in ovarian cancer, will produce the score and is being advanced for a prostate cancer indication. SOPHiA GENETICS is developing a decentralized companion diagnostic incorporating PrGIS, aiming to expand global access. Myriad plans to present research co-authored with AstraZeneca at ESMO Congress 2026; it expects the research to further characterize PrGIS and support validation.
Myriad Genetics (MYGN) promoted Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026, and reaffirmed its full-year 2026 financial guidance.
Sikri previously served as Senior Vice President of Product at Myriad for the past year and has prior molecular diagnostics, oncology and commercial leadership experience at other companies. He will lead the commercial organization following the departure of Chief Commercial Officer Brian Donnelly, who leaves Myriad on September 21, 2026. The company said Sikri’s expertise is expected to support its cancer care continuum focus and profitable growth strategy. Myriad also confirmed that its previously issued 2026 guidance from the July 30, 2026 second-quarter earnings call remains unchanged.
Myriad Genetics (NASDAQ: MYGN) announced that its management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026, at 11:00 a.m. EST. A live audio webcast of the presentation will be accessible via the investor information section of Myriad’s website at investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN) reported second quarter 2026 revenue of $190.7 million, down 11% year-over-year, driven by a 1% decline in total test volumes to 379,000 and a 9% drop in average revenue per test, including an $11.0 million revenue reduction from updated cash collection estimates.
Cancer Care Continuum revenue was $114.1 million (–11%), Prenatal Health $39.8 million (–16%) and Mental Health $36.8 million (–3%). Gross margin was 66.6%, down 460 basis points. Operating loss was $38.9 million, with adjusted operating expenses rising to $150.5 million. Operating cash outflow was $8.3 million, adjusted free cash flow was –$10.9 million, and cash and equivalents totaled $115.2 million.
The company launched Prolaris + AI, expanded Precise MRD, requested MolDX coverage for Precise MRD in breast cancer, and introduced the FirstGene Multiple Prenatal Screen. Myriad initiated its Ascend efficiency program with a professional services firm and revised 2026 guidance to revenue of $770–$790 million and adjusted gross margin of 66–67%, while suspending prior adjusted EBITDA guidance.
Myriad Genetics (NASDAQ: MYGN) will release its second quarter 2026 financial results after the market close on Thursday, July 30, 2026, followed by an earnings conference call at 4:30 p.m. ET. Management will discuss the company’s financial overview and business performance, with live and archived access available via the Investor Relations website.
Myriad Genetics (NASDAQ: MYGN) announced the full commercial launch of FirstGene Multiple Prenatal Screen, described as the only lab test that runs four prenatal genetic screens simultaneously from a single maternal blood draw as early as eight weeks gestation.
The test combines fetal chromosome, fetal single-gene, patient carrier, and fetal RhD screening into one report, with analytical sensitivity generally ≥98–99% and specificity ≥99%. Results are expected in about 10 days, do not require a reproductive partner sample, and were supported by extensive analytical validation and performance testing, according to Myriad Genetics.
Myriad Genetics (NASDAQ: MYGN) reported results from the largest individual‑patient meta-analysis of its Prolaris Biopsy Test in localized prostate cancer. Across 14 studies and 8,478 patients, the combined clinical risk (CCR) score was significantly prognostic for distant metastasis and prostate cancer-specific mortality across all NCCN risk groups and initial management strategies.
The RNA-based test analyzes biopsy gene expression plus clinical data to support decisions between active surveillance, definitive therapy, and treatment escalation. According to Myriad Genetics, Prolaris provides independent, additive prognostic information beyond tools such as Gleason score, CAPRA, and NCCN risk group, and now includes AI digital pathology features.